Pharmaceutisch Weekblad

, Volume 5, Issue 2, pp 65–69 | Cite as

In vitro testing of controlled release theophylline preparations: Theolair ®, Theograd® and Theolin®

  • J. P. Crombeen
  • C. J. De Blaey
Original Articles


Three dissolution methods,i.e. a paddle type, theusp disintegration and a column method, were used to characterize the release from three controlled release theophylline preparations,i.e. Theolair Retard® 250, Theolin Retard® 300 and Theograd® 350. The release profiles proved to be dependent upon agitation intensity and pH or a combination of both, but the sensitivity towards these variables differed markedly between the products tested.


Public Health Internal Medicine Theophylline Control Release Release Profile 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Boroda, C., R.B. Miller, S.T. Leslie, E.G. Nicholson andI. Thomson (1973)J. Clin. Pharmacol. 13, 383–387.Google Scholar
  2. Cobby, J., M. Mayerssohn andG.C. Walker (1974)J. Pharm. Sci. 63, 725–732.Google Scholar
  3. Conard, G.J., M.J. Jernberg, F.N. Wong, C.A. Milden andI.W. French (1982)Int. J. Pharm. 10, 259–273.Google Scholar
  4. Elwood, R.K., J.G. Kelly andD.G. Mcdevitt (1978)Eur. J. Clin. Pharmacol. 13, 29–33.Google Scholar
  5. Fagerström, P.O., T. Mellstrand andN. Svedmyr (1981)Int. J. Clin. Pharmacol. Ther. Toxicol. 19, 131–138.Google Scholar
  6. French, I.W., andC.A. Mildon (1979)Curr. Med. Res. Op. 6, suppl. 6, 3–13.Google Scholar
  7. Guerten, D., A.Dresse and F.Jaminet (1981) In:First European Congress of Biopharmaceutics and Pharmacokinetics, Clermont Ferrand (Aiache, J.M., and J.Hirtz, Eds.). Vol. 1, 83–87.Google Scholar
  8. Higuchi, T. (1961)J. Pharm. Sci. 50, 874–875;Ibidem (1963)52, 1145–1149.Google Scholar
  9. Jonkman, J.H.G., R. Schoenmaker, N. Grimberg andR.A. De Zeeuw (1981)Int. J. Pharm. 8, 153–156.Google Scholar
  10. Langenbucher, F. (1969)J. Pharm. Sci. 58, 1265–1272.Google Scholar
  11. Mitenko, P.A., andR.I. Ogilvie (1974)Clin. Pharmacol. Ther. 16, 720–726.Google Scholar
  12. Schneider, G.F., G.U. Heese, H.J. Huber, N. Janzen, H. Jünger, Ch. Moser andF. Stanislaus (1981)Arzneimittelforsch. 31, 1489–1497.Google Scholar
  13. Sharma, P.L., andR.M. Sharma (1979)Int. J. Clin. Pharmacol. Biopharm. 17, 394–396.Google Scholar
  14. Spangler, D.L., F.L. Bloom andH.J. Witting (1976)J. Allergy Clin. Immunol. 57, 249.Google Scholar
  15. Spangler, D.L., D.D. Kaloff, F.L. Bloom andH.J. Witting (1978)Ann. Allergy 40, 6–11.Google Scholar
  16. Svedmyr, N., T. Mellstrand andK. Svedmyr (1979)Curr. Med. Res. Op. 6, suppl. 6, 40–44.Google Scholar
  17. Trembath, P.W., andS.W. Boobis (1980)Br. J. Clin. Pharmacol. 9, 365–369.Google Scholar
  18. Upton, R.A., L. Sansom, T.W. Guentert, J.R. Powell, J.F. Thiercellin, V.P. Shah, P.E. Coates andS. Riegelman (1980a)J. Pharmacokinet. Biopharm. 8, 229–242.Google Scholar
  19. Upton, R.A., J.F. Thiercellin, T.W. Guentert, J.R. Powell, P.E. Coates andS. Riegelman (1980b)J. Pharmacokinet. Biopharm. 8, 131–149.Google Scholar
  20. Weinberger, M., L. Hendeles andL. Bighley (1978)N. Engl. J. Med. 299, 852–857.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1983

Authors and Affiliations

  • J. P. Crombeen
    • 1
  • C. J. De Blaey
    • 1
  1. 1.Department of Pharmaceutics, Pharmaceutical LaboratoryUniversity of UtrechtGH UtrechtThe Netherlands

Personalised recommendations